Aerie Pharmaceuticals Inc ((AERI)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Study Overview: Aerie Pharmaceuticals Inc. recently completed a Phase 3 clinical study titled A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-3). The study aimed to assess the safety and effectiveness of AR-15512 in treating dry eye disease, a condition affecting millions worldwide. This research is significant as it explores a novel treatment approach that could potentially offer relief to patients with this chronic condition.
Intervention/Treatment: The study tested AR-15512, an experimental ophthalmic solution designed to modulate cold thermoreceptors in the eye. Participants received either the 0.003% AR-15512 solution or a placebo, administered as one drop in each eye twice daily for 90 days.
Study Design: This was a randomized, double-masked, vehicle-controlled study conducted across approximately 20 sites in the United States. Participants were randomly assigned to receive either the AR-15512 solution or a placebo. The study’s primary purpose was treatment-focused, with both participants and investigators blinded to the treatment allocation.
Study Timeline: The study began on July 18, 2022, and was completed on July 22, 2025. The primary completion date was June 2, 2025, marking the end of data collection for the primary outcome measure. The last update was submitted on July 22, 2025, indicating the study’s completion and the availability of results.
Market Implications: The completion of this study could positively impact Aerie Pharmaceuticals’ stock performance, especially if the results demonstrate significant efficacy and safety of AR-15512. As Aerie was acquired by Alcon in November 2022, successful outcomes could enhance Alcon’s position in the ophthalmic treatment market. Investors may view this development as a promising advancement in treating dry eye disease, potentially influencing investor sentiment favorably.
The study is now completed, with results available for further review on the ClinicalTrials portal.